US Patent

US10519146 — KRAS G12C inhibitors and methods of using the same

Composition of Matter · Assigned to Amgen Inc · Expires 2038-05-21 · 12y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects KRAS G12C inhibitors, their compositions, and methods of using them to treat various cancers, including pancreatic, colorectal, and lung cancers.

USPTO Abstract

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Drugs covered by this patent

Patent Metadata

Patent number
US10519146
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-05-21
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.